生物技术进展 ›› 2015, Vol. 5 ›› Issue (2): 142-147.DOI: 10.3969/j.issn.2095-2341.2015.02.12

• 研究论文 • 上一篇    下一篇

埃博拉病毒疫苗研究进展及相关专利浅析

李有朝,蔡玉品,郝佳   

  1. 国家知识产权局专利局专利审查协作北京中心, 北京 100086
  • 收稿日期:2015-01-28 出版日期:2015-03-25 发布日期:2015-02-17
  • 作者简介:李有朝,研究实习员,硕士,主要从事医药生物的专利审查工作。E-mail:liyouzhao641@126.com

Progress of Ebola Virus Vaccines and Analysis of Related Patents

LI You-zhao, CAI Yu-pin, HAO Jia   

  1. Patent Examination Cooperation Center of the Patent Office (Beijing), State Intellectual Property, Beijing 100086, China
  • Received:2015-01-28 Online:2015-03-25 Published:2015-02-17

摘要: 通过非专利数据库的文献检索,总结了埃博拉病毒(EBOV)研究的最新进展,通过专利文献数据库文献检索分析EBOV疫苗的专利申请基本情况、发展趋势和技术点。结果发现专利申请量与疫情的爆发有一定的相关性;专利申请人多为政府主导的机构或非营利性机构;最新的专利申请均关注GP蛋白对病毒侵染的重要性,针对GP蛋白的抗体和疫苗正在开发中,其中Mapp生物制药公司的产品“ZMapp”作为试验性生物药物目前效果最佳。

关键词: 埃博拉病毒, 疫苗, 专利, ZMapp

Abstract: Through searching in the non-patent database,we summarized the latest research progress of the Ebola virus (EBOV), and depending on the patent analysis,we have understood the basic information about the key points which the inventors focus on. It was found that the amount of patent applications and outbreaks have some correlation;the patent applicant are more for the government-led or non-profit organization;the latest patent applications were concerned about the importance of the GP protein in the virus infection, antibodies and vaccines for GP proteins are being developed,among which Mapp biopharmaceutical companys products“Zmapp” are currently the best results as experimental biologic drugs.

Key words: Ebola virus, vaccine, patent, ZMapp